Paul M Ridker

Paul M Ridker

Senior Physician, Brigham and Women's Hospital Eugene Braunwald Professor of Medicine, Harvard Medical School

Brigham and Women’s Hospital, Boston, US

Biography

Dr Paul M Ridker is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital (BWH). A cardiovascular medicine specialist, he is also the Eugene Braunwald Professor of Medicine at Harvard School of Medicine (HMS).

Dr Ridker received his medical degree from HMS. He then completed an internal medicine residency and a cardiology fellowship at BWH. He has authored over 500 peer-reviewed publications, 150 reviews and book chapters, and five textbooks related to cardiovascular medicine. Dr Ridker’s primary research focus has involved inflammatory mediators of heart disease and the molecular and genetic epidemiology of hemostasis and thrombosis, with particular interests in biomarkers for coronary disease, “predictive” medicine, and the underlying causes and prevention of atherosclerotic disease.

Read more

Media

ACC 23: Inflammatory Risk from Statin-Treated Patients

Paul M Ridker,

Watch time: 8m 2s

Enoch Akowuah, Annapoorna Kini , Atul Verma, et al

Watch time: 4h 22m 12s (29 videos)
Targeting Inflammation in Atherosclerosis: Inflammatory Signalling in Atherosclerosis and CKD

Juan Carlos Kaski, Paul M Ridker,

Listen time: 8m 36s
Targeting Inflammation in Atherosclerosis: Unmet Clinical Needs in Atherosclerosis and Chronic Kidney Disease

Juan Carlos Kaski, Paul M Ridker,

Listen time: 9m 50s
Targeting Inflammation in Atherosclerosis: CANTOS Trial

Paul M Ridker,

Listen time: 6m 19s
Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events

Paul M Ridker,

Watch time: 10m 24s

Federico M Asch, Jan Belohlavek, Rupert Bauersachs, et al

Watch time: 4h 24m 8s (20 videos)
ACC 2021: Findings From the RESCUE Trial

Paul M Ridker,

Watch time: 9m 28s
AHA 2018: The Cardiovascular Inflammation Reduction Trial (CIRT)

Paul M Ridker,

Watch time: 6m 26s
The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study At ESC 2017 discusses with Paul Ridker

Paul M Ridker,

Watch time: 7m 31s